Marlene Thorsen Mørch

Marlene Thorsen Mørch

Auto-generated profile, based on publicly available information

Marlene Thorsen Mørch

Hotchkiss Brain Institute and Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2015 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
RKReza Khorooshi
Reza Khorooshi
MMMarlene Thorsen Mørch
Marlene Thorsen Mørch
THThomas Hellesøe Holm
Thomas Hellesøe Holm
CBCarsten Tue Berg
Carsten Tue Berg
RDRuthe Truong Dieu
Ruthe Truong Dieu
Trevor OwensTrevor Owens
Trevor Owens
The Type I interferons (IFN), beta (IFN-β) and the alpha family (IFN-α), act through a common receptor and have anti-inflammatory effects. IFN-β is used to treat multiple sclerosis (MS) and is effective against experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Mice with EAE show elevated levels of Type I IFNs in the central nervous system (CNS), suggesting a role for endogenous Type I IFN during inflammation. However, the therapeutic benefit of Type I IFN produced in the CNS remains to be established. The aim of this study was to examine whether experimentally induced CNS-endogenous Type I IFN influences EAE. Using IFN-β reporter mice, we showed that direct administration of polyinosinic–polycytidylic acid (poly I:C), a potent inducer of IFN-β, into the cerebrospinal fluid induced increased leukocyte numbers and transient upregulation of IFN-β in CD45/CD11b-positive cells located in the meninges and choroid plexus, as well as enhanced IFN-β expression by parenchymal microglial cells. Intrathecal injection of poly I:C to mice showing first symptoms of EAE substantially increased the normal disease-associated expression of IFN-α, IFN-β, interferon regulatory factor-7 and IL-10 in CNS, and disease worsening was prevented for as long as IFN-α/β was expressed. In contrast, there was no therapeutic effect on EAE in poly I:C-treated IFN receptor-deficient mice. IFN-dependent microglial and astrocyte response included production of the chemokine CXCL10. These results show that Type I IFN induced within the CNS can play a protective role in EAE and highlight the role of endogenous type I IFN in mediating neuroprotection.

29 May 2015 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
NANasrin Asgari
Nasrin Asgari
CBCarsten Tue Berg
Carsten Tue Berg
MMMarlene Thorsen Mørch
Marlene Thorsen Mørch
RKReza Khorooshi
Reza Khorooshi
Trevor OwensTrevor Owens
Trevor Owens
To clarify the significance of immunoglobulin G autoantibody specific for the astrocyte water channel aquaporin-4 in cerebrospinal fluid, aquaporin-4-immunoglobulin G from a neuromyelitis optica patient was administered intrathecally to naïve mice, and the distribution and pathogenic impact was evaluated. A distinct distribution pattern of aquaporin-4-immunoglobulin G deposition was observed in the subarachnoid and subpial spaces where vessels penetrate the brain parenchyma, via a paravascular route with intraparenchymal perivascular deposition. Perivascular astrocyte-destructive lesions were associated with blood-borne horseradish peroxidase leakage indicating blood-brain barrier breakdown. The cerebrospinal fluid aquaporin-4-immunoglobulin G therefore distributes widely in brain to initiate astrocytopathy and blood-brain barrier breakdown.

1 August 2016 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
KSKerstin Soelberg
Kerstin Soelberg
SLStine R. Larsen
Stine R. Larsen
MMMarlene T. Moerch
Marlene T. Moerch
MTMads Thomassen
Mads Thomassen
KBKlaus Brusgaard
Klaus Brusgaard
NANasrin Asgari
Nasrin Asgari

7 October 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
RKReza Khorooshi
Reza Khorooshi
NANasrin Asgari
Nasrin Asgari
MMMarlene Thorsen Mørch
Marlene Thorsen Mørch
CBCarsten Tue Berg
Carsten Tue Berg
Trevor OwensTrevor Owens
Trevor Owens
Immune-mediated tissue damage or hypersensitivity can be mediated by autospecific IgG antibodies. Pathology results from activation of complement, and antibody-dependent cellular cytotoxicity (ADCC), mediated by inflammatory effector leukocytes include macrophages, natural killer cells (NK) cells and granulocytes. Antibodies and complement have been associated to demyelinating pathology in multiple sclerosis (MS) lesions, where macrophages predominate amongst infiltrating myeloid cells. Serum-derived autoantibodies with predominant specificity for the astrocyte water channel aquaporin-4 (AQP4) are implicated as inducers of pathology in neuromyelitis optica (NMO), a CNS demyelinating disease where activated neutrophils infiltrate, unlike in MS. The most widely-used model for MS, experimental autoimmune encephalomyelitis (EAE), is an autoantigen-immunized disease that can be transferred to naive animals with CD4+ T cells, but not with antibodies. By contrast NMO-like astrocyte and myelin pathology can be transferred to mice with AQP4-IgG from NMO patients. This is dependent on complement, and does not require T cells. Consistent with clinical observations that interferon-beta is ineffective as a therapy for NMO, NMO-like pathology is significantly reduced in mice lacking the Type I IFN receptor. In MS there is evidence for intrathecal synthesis of antibodies as well as blood-brain barrier (BBB) breakdown, whereas in NMO, IgG accesses the CNS from blood. Transfer models involve either direct injection of antibody and complement to the CNS, or experimental manipulations to induce BBB breakdown. We here review studies in MS and NMO that elucidate roles for IgG and complement in the induction of BBB breakdown, astrocytopathy and demyelinating pathology. These studies point to significance of T-independent effector mechanisms in neuroinflammation.

17 April 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MMMarlene Thorsen Mørch
Marlene Thorsen Mørch
SSSofie Forsberg Sørensen
Sofie Forsberg Sørensen
RKReza Khorooshi
Reza Khorooshi
NANasrin Asgari
Nasrin Asgari
Trevor OwensTrevor Owens
Trevor Owens
Encounter of autoantibodies with specific antigens can lead to hypersensitivity reactions and pathology. In multiple sclerosis and neuromyelitis optica spectrum disease (NMOSD), immunoglobulin-G (IgG) deposition has been observed in pathological lesions in the central nervous system. The paradigmatic autoantibodies in NMOSD are specific for the water channel aquaporin-4, localized to astrocytic end-feet at the blood-brain barrier and ependymal cells at the cerebrospinal fluid-brain barrier. We have previously observed that IgG antibodies from NMO patients (NMO-IgG) access brain parenchyma from the cerebrospinal fluid and induce subpial and periventricular NMO-like lesions and blood-brain barrier breakdown, in a complement-dependent manner. To investigate how IgG trafficking from cerebrospinal fluid to brain parenchyma can be influenced by injury. IgG from healthy donors was intrathecally injected into the cerebrospinal fluid via cisterna magna at 1, 2, 4, or 7 days after a distal stereotactic sterile needle insertion to the striatum. Antibody deposition, detected by staining for human IgG, peaked 1 day after the intrathecal injection and was selectively seen close to the needle insertion. When NMO-IgG was intrathecally injected, we observed complement-dependent NMO-like pathology (loss of aquaporin-4 and glial fibrillary acidic protein) proximal to the insertion site, with similar kinetics. A fluorescent tracer did not show the same distribution indicating IgG-selective localization. These findings suggest that IgG from cerebrospinal fluid localize selectively in brain parenchyma at the site of injury and pathogenic NMO-IgG induce astrocyte pathology at the same location.

15 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
RCRobert Clarke
Robert Clarke
ARAtefeh Rayatpour
Atefeh Rayatpour
JGJosep Garnica
Josep Garnica
BLBrian M Lozinski
Brian M Lozinski
JLJustin Lee
Justin Lee
Pere SantamariaPere Santamaria
Pere Santamaria
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results from oligodendrocyte loss and multifocal demyelination of the CNS white matter. Current therapies can suppress the progression of CNS inflammation but do not actively promote tissue repair. Nanoparticles (NPs) coated with CNS-specific peptide-major histocompatibility complex class II (pMHCII) molecules can alleviate disability in mice with experimental autoimmune encephalomyelitis (EAE) by triggering the formation, expansion, and recruitment of antigen-specific type 1 regulatory CD4+ T cells (Tr1 cells). By investigating the effects of pMHCII-NP therapy on focal demyelinated lesions in the spinal cord induced by lysolecithin and sustained by chronic autoimmune encephalitogenic insults, here, we show that CNS antigen-specific Tr1 cells promote oligodendrogenesis, the preservation of axon caliber, and remyelination. Cell-specific deletion of amphiregulin (Areg) in T cells or of the epidermal growth factor receptor (Egfr) in oligodendrocytes abrogated these therapeutic outcomes. Oligodendrocyte-specific deletion of Egfr did not impair the pharmacodynamic or anti-inflammatory effects of pMHCII-NP treatment. These findings indicate that the oligodendrocyte-mediated therapeutic effects of pMHCII-NP treatment are dissociated from the anti-inflammatory properties of Tr1 cells; instead, they involve Tr1 cell-derived Areg to activate oligodendrocytes in an EGFR-dependent manner. Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.